COVID-19 is forcing the entire health care ecosystem to work closely together to identify creative solutions that go beyond the “research as usual” approach. As we continue to pivot into a new post-COVID-19 world, it’s critical that we move beyond outdated protocols and start to embrace a future that can maximize outcomes for patients. Updating the patient identification approach via artificial intelligence; demanding that data collection work harder and smarter; and providing flexibility within the current clinical trial system will allow us to potentially increase participation rates and reach that ultimate goal—discovering new and more effective cancer treatments that improve patient outcomes and save lives.